ITRM (Iterum Therapeutics plc Ordinary Share) Stock Analysis - News

Iterum Therapeutics plc Ordinary Share (ITRM) is a publicly traded Healthcare sector company. As of May 21, 2026, ITRM trades at $0.03 with a market cap of $1.60M and a P/E ratio of -0.04. ITRM moved -28.57% today. Year to date, ITRM is -94.99%; over the trailing twelve months it is -97.56%. Its 52-week range spans $0.03 to $3.02. Analyst consensus is hold with an average price target of $0.00. Rallies surfaces ITRM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in ITRM news today?

Iterum Therapeutics Files Irish Winding-Up Petition, Hearing Set April 13: Iterum Therapeutics filed a petition in the Irish High Court to wind up the company and appointed Joint Provisional Liquidators, with a hearing set for April 13, 2026. The board cited limited cash, Nasdaq compliance failure, lack of share issuance authority and no viable strategic transactions, flagging potential ORLYNVAH withdrawal.

ITRM Key Metrics

Key financial metrics for ITRM
MetricValue
Price$0.03
Market Cap$1.60M
P/E Ratio-0.04
EPS$-0.72
Dividend Yield0.00%
52-Week High$3.02
52-Week Low$0.03
Volume65.74M
Avg Volume0
Revenue (TTM)$390.00K
Net Income$-26.96M
Gross Margin0.00%

Latest ITRM News

Recent ITRM Insider Trades

  • Dunne Michael W. bought 6.00K (~$2.19K) on Nov 18, 2025.
  • Dunne Michael W. bought 15.00K (~$10.85K) on Aug 8, 2025.
  • Dunne Michael W. bought 25.00K (~$35.00K) on Dec 22, 2023.

ITRM Analyst Consensus

1 analysts cover ITRM: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $0.00.

Common questions about ITRM

What changed in ITRM news today?
Iterum Therapeutics Files Irish Winding-Up Petition, Hearing Set April 13: Iterum Therapeutics filed a petition in the Irish High Court to wind up the company and appointed Joint Provisional Liquidators, with a hearing set for April 13, 2026. The board cited limited cash, Nasdaq compliance failure, lack of share issuance authority and no viable strategic transactions, flagging potential ORLYNVAH withdrawal.
Does Rallies summarize ITRM news?
Yes. Rallies summarizes ITRM news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ITRM research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ITRM. It does not provide personalized investment advice.
ITRM

ITRM